the-infoshop.com - The vertical markets research portal
View CartView Cart
Global Information, Inc.
US: +1-860-674-8796
EU: +32-2-535-7543
SG: +65-6223-2436
  Home | Category | Publishers | Custom Research | E-mail Alert | About Us | Contact Us | Site Map |
 

* View All Categories
View Conferences
Japanese Korean Chinese

Market Research Report

Autoimmune Treatment (2009 - 2014)

Published by Markets and Markets Contact us : +1-860-674-8796
Published 2009/09 Content info 159 pages
Product code MAMA99907
Price From  US $ 4650 Order/Price list
US $ 4650 PDF by E-mail (Single User License)
US $ 5650 PDF by E-mail (Multi User License)
US $ 7150 PDF by E-mail (Corporate Use License)
Delivery Time
PDF by E-Mail
Approx. 1-2 business days
Hard Copy/CD-ROM
Approx. 3-4 business days
If you need expedited delivery, please call us.
Description TOC

Table of Contents

1. Chapter one - Introduction

  • 1.1. KEY TAKE AWAYS
  • 1.2. Report description
  • 1.3. Markets Covered
  • 1.4. STAKEHOLDERS

2. Chapter Two - Summary

3. Chapter Three - Market Overview

  • 3.1. Evolution for Autoimmune treatments
  • 3.2. FOCUS AREAS for the DEVELOPMENT autoimmune treatment
  • 3.3. Defining the overall autoimmune treatment market
  • 3.4. Defining the Autoimmune treatment market by geography

4. Chapter four - global autoimmune treatment market by application

  • 4.1. Systemic Autoimmune Diseases
  • 4.2. Rheumatoid Arthritis (RA)
    • 4.2.1. Drivers
      • 4.2.1.1. Large number of people suffer from RA
      • 4.2.1.2. RA requires continuous treatment as it is a chronic disease
      • 4.2.1.3. Large middle adulthood population is more prone to RA
    • 4.2.2. Restraints
      • 4.2.2.1. No fixed treatment is available for RA
      • 4.2.2.2. Fewer insurance coverage and reimbursement for RA treatment
    • 4.2.3. Global RA Market for Consultation & Diagnosis
    • 4.2.4. Global RA market for therapy & monitoring
      • 4.2.4.1. Global DMARD and biologic DMARD Therapy in RA
      • 4.2.4.2. Global Bridge Therapy market in RA
      • 4.2.4.3. Global Other Therapies market in RA
    • 4.2.5. Global RA Market for Drugs
      • 4.2.5.1. Global NSAID market in RA
      • 4.2.5.2. Global Corticosteroids Market in RA
      • 4.2.5.3. Global Other Drugs Market in RA
    • 4.2.6. Global other products and services market in RA
    • 4.2.7. Drug Approvals
  • 4.3. Psoriasis
    • 4.3.1. Drivers
      • 4.3.1.1. Psoriasis starts at early age, gives a long earning period
      • 4.3.1.2. Large patient base is driving the market
      • 4.3.1.3. Psoriasis is also genetically transferred
    • 4.3.2. Market restraints
      • 4.3.2.1. Over the counter (OTC) drugs can result into adverse drug reactions (ADRs)
      • 4.3.2.2. No specific diagnosis and treatment hinders the market growth
    • 4.3.3. Global Consultation & Diagnosis Market in Psoriasis
    • 4.3.4. Global therapy & monitoring market in psoriasis
    • 4.3.5. Global Drugs Market in Psoriasis
      • 4.3.5.1. Global Anthralin Market in Psoriasis
      • 4.3.5.2. Global Calcipotriene Market in Psoriasis
      • 4.3.5.3. Global NSAIDs market in Psoriasis
  • 4.4. Lupus
  • 4.5. Other Systemic Diseases
  • 4.6. Localized autoimmune Diseases
  • 4.7. Multiple Sclerosis (MS)
    • 4.7.1. Drivers
      • 4.7.1.1. MS is a chronic disorder which requires lifetime treatment
      • 4.7.1.2. Large number of MS patients across the globe
      • 4.7.1.3. Increased public awareness is leading to early initiation of treatment
      • 4.7.1.4. Combination of therapies is increasing the growth opportunities
    • 4.7.2. Restraints
      • 4.7.2.1. Complicated nature of disease with limited drugs is hindering the market growth
      • 4.7.2.2. Side effects of injectables and high cost of oral drugs is affecting the growth
    • 4.7.3. Global Drugs market in multiple sclerosis
    • 4.7.4. Drug Approval
  • 4.8. Inflammatory Bowel Disease (IBD)
    • 4.8.1. Drivers
      • 4.8.1.1. IBD a genetically transferred disease, increases the incidence of cases
      • 4.8.1.2. Early treatment of IBD is driving the market
      • 4.8.1.3. Lifelong treatment gives a long earning period
    • 4.8.2. Restraints
      • 4.8.2.1. Insurance coverage reimbursement problems for IBD patients
    • 4.8.3. Global Consultation & Diagnosis Market in IBD
    • 4.8.4. Global therapy & monitoring market in IBD
    • 4.8.5. Global drugs market in IBD
  • 4.9. Type I diabetes
    • 4.9.1. Easy insurance coverage for diabetes patients
    • 4.9.2. Type I diabetes is still considered to be a chronic disorder
    • 4.9.3. Casual behavior towards treatment is restraining the Market growth
  • 4.10. Thyroid
  • 4.11. Other Localized Autoimmune diseases

5. Chapter five - Global Autoimmune treatment Market By Product

  • 5.1. Drugs
    • 5.1.1. Non-Steroidal anti-inflammatory drugs (NSAID)
      • 5.1.1.1. Drivers
      • 5.1.1.2. Restraints
    • 5.1.2. GLUCOCORTICOIDS
    • 5.1.3. METHOTREXATE
      • 5.1.3.1. Drivers & Restraints
    • 5.1.4. Hydroxychloroquine (HCQ)
      • 5.1.4.1. Drivers
      • 5.1.4.2. Restraints
    • 5.1.5. Anthralin
    • 5.1.6. Calicipotriene
    • 5.1.7. Corticosteriods (Steriods)
    • 5.1.8. Aminosalicylates/5-ASA/Mesalazine
    • 5.1.9. Avonex
    • 5.1.10. Rebif
    • 5.1.11. Copaxone
      • 5.1.11.1. Fewer side effects is increasing the demand
      • 5.1.11.2. Reduces relapses in relapsing-remitting multiple sclerosis (RRMS)
    • 5.1.12. Betaseron
    • 5.1.13. Comparison of four MS drugs
    • 5.1.14. Other Drugs
  • 5.2. Diagnostic equipment
  • 5.3. Therapeutic and monitoring equipment
  • 5.4. Other Products

6. Chapter six - global services market in autoimmune treatment

  • 6.1. Consultation & Diagnosis
  • 6.2. Therapy and monitoring
  • 6.3. Drug Development
  • 6.4. Drivers
    • 6.4.1. Drugs form the mainstream, most revenue-generating treatment
    • 6.4.2. Introduction of biosimilars opens up more opportunities

7. Chapter seven - global Technology market in autoimmune treatment

  • 7.1. DMARD AND BIOLOGIC DMARD THERAPY
    • 7.1.1. Drivers
      • 7.1.1.1. Effective therapies with biologic DMARD and the availability of multiple drugs
      • 7.1.1.2. Cost-effective treatment is boosting the demand for the therapy
    • 7.1.2. Restraints
  • 7.2. Bridge Therapy
  • 7.3. Topical Therapy
  • 7.4. Fecal Bacteriotherapy
  • 7.5. Helminthic Therapy
    • 7.5.1. Drivers & Restraints
      • 7.5.1.1. Higher efficacy
      • 7.5.1.2. Expensive treatment hindering the market growth
  • 7.6. Hematopoietic stem cell transplantation
    • 7.6.1. Drivers & Restraints
  • 7.7. Recombinant Technology

8. Chapter Eight - Global Autoimmune Treatment Market by Geography

  • 8.1. Autoimmune treatment market in North America
    • 8.1.1. North American Autoimmune treatment Market by
    • 8.1.2. Application
  • 8.2. Autoimmune treatment market in Europe
    • 8.2.1. European autoimmune treatment market by application
  • 8.3. Autoimmune treatment market in Asia Pacific
  • 8.4. Autoimmune treatment market in ROW

9. Chapter Nine - Patent Analysis

  • 9.1. Analysis of patents by geography

10. Chapter Ten - Company Profiles

  • 10.1. 4SC AG
  • 10.2. Abbott Laboratories
  • 10.3. Active Biotech
  • 10.4. Amgen
  • 10.5. Angiotech Pharmaceuticals
  • 10.6. Astellas Pharma
  • 10.7. AstraZeneca Plc
  • 10.8. Autoimmune Inc
  • 10.9. Bayer-Schering Pharmaceuticals
  • 10.10. BioCryst Pharmaceuticals Inc.
  • 10.11. Biogen Idec, Inc.
  • 10.12. Boehringer Ingelheim Gmbh
  • 10.13. Bristol-Myers Squibb Co.
  • 10.14. Centocor, Inc
  • 10.15. Cytokine PharmaSciences, Inc
  • 10.16. Elan Corporation, plc
  • 10.17. Eli Lilly & Co.
  • 10.18. Forest Laboratories, Inc.
  • 10.19. Galderma Laboratories
  • 10.20. Genentech, Inc.
  • 10.21. Glaxo SmithKline Plc
  • 10.22. Isis Pharmaceuticals, Inc.
  • 10.23. Isotechnika, Inc.
  • 10.24. Johnson & Johnson
  • 10.25. Ligand Pharmaceuticals
  • 10.26. Lupin
  • 10.27. Merk Serono SA
  • 10.28. Mitsubishi Tanabe Pharma Corporation
  • 10.29. Novartis
  • 10.30. Pfizer
  • 10.31. Roche
  • 10.32. Sanofi-Aventis
  • 10.33. Schering-Plough
  • 10.34. Teva
  • 10.35. UCB Pharma Inc
  • 10.36. Vertex Pharmaceuticals Incorporated
  • 10.37. Warner Chilcott
  • 10.38. Watson Pharmaceuticals, Inc
  • 10.39. Wyeth
  • 10.40. ZymoGenetics, Inc.

Appendix

  • 1. Table 1
  • 2. U.S. patents
  • 3. Source: MarketsandMarkets
  • 4. Europe Patent List
  • 5. Source: MarketsandMarkets
  • 6. Table 2
  • 7. Japan Patent Table
  • 8. Source: MarketsandMarkets

List of Tables

  • SUMMARY TABLE GLOBAL MARKET FOR AUTOIMMUNE TREATMENT, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
  • TABLE 1 GLOBAL AUTOIMMUNE TREATMENT MARKET 2007 - 2014 ($ MILLIONS)
  • TABLE 2 GLOBAL SYSTEMIC DISEASES MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
  • TABLE 3 GLOBAL SYSTEMIC DISEASES MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 4 GLOBAL RHEUMATOID ARTHRITIS MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
  • TABLE 5 GLOBAL RHEUMATOID ARTHRITS APPLICATIONS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 6 GLOBAL RA CONSULTATION & DIAGNOSIS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 7 GLOBAL RA THERAPY AND MONITORING MARKET, BY TECHNOLOGY 2007 - 2014 ($ MILLIONS)
  • TABLE 8 GLOBAL RA THERAPY AND MONITORING MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 9 GLOBAL RA DMARD AND BIOLOGIC DMARD THERAPY MARKET BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 10 GLOBAL RA BRIDGE THERAPY MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 11 GLOBAL OTHER RA THERAPIES MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 12 GLOBAL RA DRUGS MARKET, BY PRODUCTS 2007 - 2014 ($ MILLIONS)
  • TABLE 13 GLOBAL RA DRUGS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 14 GLOBAL RA NSAID MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 15 GLOBAL RA CORTICOSTERIODS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 16 GLOBAL OTHER RA DRUGS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 17 GLOBAL OTHER RA PRODUCTS AND SERVICES MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 18 MAJOR COMPANIES AND THEIR RA PRODUCTS
  • TABLE 19 MERGERS AND ACQUISITIONS IN THE RA MARKET
  • TABLE 20 GLOBAL PSORIASIS MARKET, BY PRODUCTS 2007 - 2014 ($ MILLIONS)
  • TABLE 21 GLOBAL PSORIASIS APPLICATIONS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 22 GLOBAL PSORIASIS CONSULTATION & DIAGNOSIS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 23 GLOBAL PSORIASIS THERAPY & MONITORING MARKET, BY TECHNOLOGY 2007 - 2014 ($ MILLIONS)
  • TABLE 24 GLOBAL PSORIASIS THERAPY AND MONITORING MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 25 GLOBAL PSORIASIS DRUGS MARKET, BY PRODUCTS 2007 - 2014 ($ MILLIONS)
  • TABLE 26 GLOBAL PSORIASIS DRUGS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 27 GLOBAL ANTHRALIN PSORIASIS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 28 GLOBAL CALCIPOTRIENE PSORIASIS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 29 GLOBAL NSAID PSORIASIS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 30 MAJOR COMPANIES AND THEIR PSORIASIS PRODUCTS
  • TABLE 31 MERGERS & ACQUISITIONS IN THE PSORIASIS MARKET
  • TABLE 32 GLOBAL LUPUS MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
  • TABLE 33 GLOBAL LUPUS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 34 GLOBAL OTHER SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
  • TABLE 35 GLOBAL OTHER SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 36 GLOBAL LOCALIZED DISEASES MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
  • TABLE 37 GLOBAL LOCALIZED DISEASES MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 38 GLOBAL MULTIPLE SCLEROSIS APPLICATIONS MARKET 2007 - 2014 ($ MILLIONS)
  • TABLE 39 GLOBAL MULTIPLE SCLEROSIS APPLICATIONS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 40 GLOBAL MS DRUGS MARKET, BY PRODUCTS 2007 - 2014 ($ MILLIONS)
  • TABLE 41 MAJOR COMPANIES AND THEIR MS PRODUCTS
  • TABLE 42 MERGERS & ACQUISITIONS IN THE MS MARKET
  • TABLE 43 GLOBAL INFLAMMATORY BOWEL DISEASE MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
  • TABLE 44 GLOBAL INFLAMMATORY BOWEL DISEASE MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 45 GLOBAL IBD CONSULTATION & DIAGNOSIS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 46 GLOBAL IBD THERAPY & MONITORING MARKET 2007 - 2014 ($ MILLIONS)
  • TABLE 47 GLOBAL IBD DRUGS MARKET, BY PRODUCTS 2007 - 2014 ($ MILLIONS)
  • TABLE 48 GLOBAL IBD DRUGS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 49 MAJOR COMPANIES AND THEIR IBD PRODUCTS
  • TABLE 50 MERGERS AND ACQUISITIONS IN IBD MARKET
  • TABLE 51 GLOBAL TYPE I DIABETES MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
  • TABLE 52 GLOBAL TYPE I DIABETES MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 53 MAJOR COMPANIES AND THEIR TYPE I DIABETES PRODUCTS
  • TABLE 54 MERGERS AND ACQUISITIONS IN THE TYPE I DIABETES MARKET
  • TABLE 55 GLOBAL THYROID MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
  • TABLE 56 GLOBAL THYROID MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 57 GLOBAL OTHER LOCALIZED AUTOIMMUNE DISEASES MARKET BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
  • TABLE 58 GLOBAL OTHER LOCALIZED AUTOIMMUNE DISEASES MARKET BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 59 GLOBAL AUTOIMMUNE TREATMENT MARKET, BY PRODUCT 2007 - 2014 ($ MILLIONS)
  • TABLE 60 GLOBAL AUTOIMMUNE TREATMENT PRODUCTS MARKET BY GEOGRAPHY 2007 - 2014, ($ MILLIONS)
  • TOTAL 61 GLOBAL AUTOIMMUNE DRUGS MARKET, BY PRODUCTS 2007 - 2014 ($ MILLIONS)
  • TOTAL 62 GLOBAL AUTOIMMUNE DRUGS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 63 GLOBAL NSAID MARKET IN AUTOIMMUNE TREATMENT, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 64 GLOBAL GLUCOCORTICOIDS MARKET IN AUTOIMMUNE TREATMENT BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 65 GLOBAL METHOREXATE MARKET IN AUTOIMMUNE TREATMENT BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 66 GLOBAL HCQ MARKET IN AUTOIMMUNE TREATMENT, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 67 GLOBAL HCQ MARKET IN AUTOIMMUNE TREATMENT, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 68 GLOBAL CALCIPOTRIENE MARKET IN AUTOIMMUNE TREATMENT BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 69 GLOBAL CORTICOSTERIODS MARKET IN AUTOIMMUNE TREATMENT BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 70 GLOBAL AMINOSALICYLATES/5-ASA/MESALAZINE MARKET IN AUTOIMMUNE TREATMENT, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)TTABLE 71 GLOBAL AVONEX MARKET IN AUTOIMMUNE TREATMENT, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 72 GLOBAL REBIF MARKET IN AUTOIMMUNE TREATMENT, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 73 GLOBAL COPAXONE MARKET IN AUTOIMMUNE TREATMENT BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 74 GLOBAL BETASERON MARKET IN AUTOIMMUNE TREATMENT BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 75 GLOBAL OTHER AUTOIMMUNE DRUGS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 76 GLOBAL AUTOIMMUNE DIAGNOSTIC EQUIPMENT MARKET, BY PRODUCTS 2007 - 2014 ($ MILLIONS)
  • TABLE 77 GLOBAL AUTOIMMUNE DIAGNOSTIC EQUIPMENT MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 78 GLOBAL AUTOIMMUNE THERAPEUTIC AND MONITORING EQUIPMENT MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 79 GLOBAL OTHER AUTOIMMUNE PRODUCTS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 80 GLOBAL SERVICES MARKET IN AUTOIMMUNE TREATMENT 2007 - 2014 ($ MILLIONS)
  • TABLE 81 GLOBAL SERVICES MARKET IN AUTOIMMUNE TREATMENT BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 82 GLOBAL AUTOIMMUNE CONSULTATION & DIAGNOSIS MARKET BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 83 GLOBAL AUTOIMMUNE THERAPY & MONITORING MARKET BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 84 GLOBAL AUTOIMMUNE DRUG DEVELOPMENT MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 85 GLOBAL AUTOIMMUNE TREATMENT TECHNOLOGY MARKET, BY PRODUCTS 2007 - 2014 ($ MILLIONS)
  • TABLE 86 GLOBAL AUTOIMMUNE TREATMENT TECHNOLOGY MARKET BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 87 GLOBAL DMARD AND BIOLOGIC DMARD TECHNOLOGY MARKET BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 88 GLOBAL AUTOIMMUNE BRIDGE THERAPY MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 89 GLOBAL AUTOIMMUNE TOPICAL THERAPY MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 90 GLOBAL AUTOIMMUNE PHOTOTHERAPY MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 91 GLOBAL AUTOIMMUNE HELMINTHIC THERAPY MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 92 GLOBAL AUTOIMMUNE HEMATOPOIETIC STEM CELL TRANSPLANTATION MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 93 GLOBAL AUTOIMMUNE RECOMBINANT TECHNOLOGY MARKET BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 94 GLOBAL AUTOIMMUNE TREATMENT MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
  • TABLE 95 NORTH AMERICAN AUTOIMMUNE TREATMENT MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
  • TABLE 96 EUROPEAN AUTOIMMUNE TREATMENT MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
  • TABLE 97 ASIA PACIFIC AUTOIMMUNE TREATMENT MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
  • TABLE 98 ROW AUTOIMMUNE TREATMENT MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
  • TABLE 99 U.S. PATENTS
  • TABLE 100 EUROPE PATENT LIST
  • TABLE 101 JAPAN PATENT TABLE

List of Figures

  • FIGURE 1 FACTORS CAUSING AUTOIMMUNE DISEASES
  • FIGURE 2 CHRONOLOGY OF EVOLUTION OF THERAPIES AND DRUGS
  • FIGURE 3 FOCUS LEVELS FOR GROWTH IN AUTOIMMUNE TREATMENT
  • FIGURE 4 GLOBAL AUTOIMMUNE MARKET, BY GEOGRAPHY FOR 2009
  • FIGURE 5 CLASSIFICATION OF AUTOIMMUNE DISEASES BY APPLICATIONS
  • FIGURE 6 POSITIONING APPLICATIONS IN THE MARKET FOR AUTOIMMUNE TREATMENT
  • FIGURE 7 MARKET SHARE OF AUTOIMMUNE DRUGS IN 2009
  • FIGURE 8 COMPARISON OF FOUR MAJOR DRUGS IN MS APPLICATIONS
  • FIGURE 9 EUROPEAN MARKETS FOR AUTOIMMUNE TREATMENT, IN 2009 (%)
  • FIGURE 10 NUMBER OF PATENTS ISSUED (JANUARY 2004 - JUNE 2009)
  • FIGURE 11 NUMBER OF PATENTS ISSUED BY GEOGRAPHY (JANUARY 2004 - JUNE 2009)
  • FIGURE 12 GEOGRAPHICAL ANALYSIS (JANUARY 2004 - JUNE 2009)
Related Report
Back to Top
Please inform me when related publications are released
InfoWatch

US: 1-860-674-8796 EU: 32-2-535-7543 SG: 65-6223-2436
The vertical markets research portal
© 2009, the-infoshop.com by Global Information, Inc. All rights reserved.